University of Bristol selects Xeropoint to develop PARKINSON'S DISEASE INNOVATIVE CLINICAL TRIAL PLATFORM

The University of Bristol has today announced its selection of Xeropoint Ltd to develop an innovative clinical trial platform that will facility the study of the Cholinesterase Inhibitors as a means to halve the number of falls in patients with Parkinson’s Disease.